dpp-4 inhibitor and glp-1 receptor agonist combination Role of Inhibitors in Clinical Practice Frontiers | DPP-4 inhibitors for

SGLT-2 inhibitors cause robust reduction of HHF and the renal outcome, and moderate reduction of CV or total deaths and MACE [13]

[DOI] [PMC free article] [PubMed] 106.Kotliar I.B., Lorenzen E., Schwenk J.M., Hay D.L., Sakmar T.P

So far, several unimolecular dual and triple agonists are in clinical evaluation and as of today, the improved metabolic efficacy does not seem to be compromised by reduced safety [25].

Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data

As was previously demonstrated for a sublingual insulin formulation (sublintherapeutics.com/sublin-bv-developing-a-first-in-class-sublingual-insulin-delivery-formulation/)), these in vivo incretin studies clearly show that the sublingual formulation technology can incorporate different drug classes and provide an effective alternative for patients to their daily injections